Literature DB >> 8575583

Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients.

S Ewig1, T Bauer, C Schneider, A Pickenhain, L Pizzulli, U Loos, B Lüderitz.   

Abstract

The factors contributing to unequal mortality rates following Pneumocystis carinii pneumonia (PCP) in different groups at risk are poorly understood. We therefore compared the first episodes of PCP without prophylaxis in human immunodeficiency virus infected (HIV) and otherwise immunosuppressed patients in this retrospective study. A total of 58 HIV-infected and 16 otherwise immunosuppressed patients were analysed. The comparison included epidemiological, clinical, laboratory, radiological and microbiological data, as well as therapy and clinical course. A prognostic analysis was performed using a logistic regression model. The mortality was significantly different in the two groups (HIV group 17 versus non-HIV group 50%). Renal transplant patients had a higher survival rate as compared to malignancy or collagen vascular disease as underlying diseases at risk. Acute respiratory failure was more common in the non-HIV group. Variables found to be significantly associated with lethal outcome in univariate analysis were alveolar to arterial pressures difference for oxygen (P(A-a),O2), haemoglobin, platelet count, total protein, serum albumin, and gamma-globulins in the HIV-group, and serum albumin in the non-HIV group. In the multivariate analysis of the HIV group, platelet count and gamma-globulins remained independent prognostic factors. In conclusion, in the HIV-group, mortality is closely related to the severeness of PCP as well as to the severeness of the acquired immune deficiency syndrome (AIDS) disease. In the non-HIV group, malignancy and collagen vascular disease as underlying conditions at risk account for the high mortality rate. Its severeness was mainly reflected by serum albumin, which represented the only variable found to be significantly associated with death in both groups.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8575583

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

1.  Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients.

Authors:  Song Mi Moon; Tark Kim; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim; Sang-Oh Lee
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

2.  Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases.

Authors:  Yoko Aoki; Masahiro Iwamoto; Yasuyuki Kamata; Takao Nagashima; Taku Yoshio; Hitoaki Okazaki; Seiji Minota
Journal:  Rheumatol Int       Date:  2009-01-14       Impact factor: 2.631

3.  Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection.

Authors:  Rebecca Scherzer; Steven B Heymsfield; David Rimland; William G Powderly; Phyllis C Tien; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

4.  Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.

Authors:  Jannik Helweg-Larsen; Thomas Benfield; Chiara Atzori; Robert F Miller
Journal:  J Antimicrob Chemother       Date:  2009-10-26       Impact factor: 5.790

5.  Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis.

Authors:  A Singanayagam; K Manalan; D W Connell; J D Chalmers; S Sridhar; A I Ritchie; A Lalvani; M Wickremasinghe; O M Kon
Journal:  Int J Tuberc Lung Dis       Date:  2016-12       Impact factor: 2.373

6.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

7.  Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis.

Authors:  Yao Liu; Lili Su; Shu-Juan Jiang; Hui Qu
Journal:  Oncotarget       Date:  2017-08-04

8.  Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection.

Authors:  Xavier Monnet; Emmanuelle Vidal-Petiot; David Osman; Olfa Hamzaoui; Antoine Durrbach; Cécile Goujard; Corinne Miceli; Patrice Bourée; Christian Richard
Journal:  Crit Care       Date:  2008-01-25       Impact factor: 9.097

9.  Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma.

Authors:  Christopher D Swan; Alistair B Reid
Journal:  IDCases       Date:  2014-05-29

Review 10.  Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.

Authors:  Xavier Iriart; Marine Le Bouar; Nassim Kamar; Antoine Berry
Journal:  J Fungi (Basel)       Date:  2015-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.